Relapsed/Refractory Small Cell Lung Cancer
3 clinical trials · Condition
◉ Watch Relapsed/Refractory Small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (NCT07249879) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-03 |
| A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer (NCT07325136) | Bristol-Myers Squibb | 2026-02-03 |
| A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (NCT05060016) | Amgen | 2021-12-01 |
Track Relapsed/Refractory Small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.